drug combinations

Summary

Summary: Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture.

Top Publications

  1. ncbi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Wasaburo Koizumi
    Kitasato University School of Medicine, Sagamihara, Japan
    Lancet Oncol 9:215-21. 2008
  2. ncbi Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials
    John J Aponte
    Barcelona Centre for International Health Research, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet 374:1533-42. 2009
  3. ncbi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
    Shinichi Sakuramoto
    Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    N Engl J Med 357:1810-20. 2007
  4. pmc Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data
    Anna Maria van Eijk
    Child and Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, UK
    Lancet Infect Dis 11:190-207. 2011
  5. ncbi Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi
    James G Kublin
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 187:1870-5. 2003
  6. pmc Improved diagnostic testing and malaria treatment practices in Zambia
    Davidson H Hamer
    Center for International Health and Development, Boston University School of Public Health, Boston, Mass 02118, USA
    JAMA 297:2227-31. 2007
  7. pmc Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial
    Kojo Yeboah-Antwi
    Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000340. 2010
  8. pmc Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial
    Margaret Kweku
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS ONE 4:e7256. 2009
  9. pmc Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
  10. ncbi Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
    Jayanta Debnath
    Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Methods 30:256-68. 2003

Detail Information

Publications296 found, 100 shown here

  1. ncbi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Wasaburo Koizumi
    Kitasato University School of Medicine, Sagamihara, Japan
    Lancet Oncol 9:215-21. 2008
    ....
  2. ncbi Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials
    John J Aponte
    Barcelona Centre for International Health Research, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet 374:1533-42. 2009
    ..Intermittent preventive treatment (IPT) is a promising strategy for malaria control in infants. We undertook a pooled analysis of the safety and efficacy of IPT in infants (IPTi) with sulfadoxine-pyrimethamine in Africa...
  3. ncbi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
    Shinichi Sakuramoto
    Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
    N Engl J Med 357:1810-20. 2007
    ..Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine. We tested S-1 as adjuvant chemotherapy in patients with curatively resected gastric cancer...
  4. pmc Coverage of malaria protection in pregnant women in sub-Saharan Africa: a synthesis and analysis of national survey data
    Anna Maria van Eijk
    Child and Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, UK
    Lancet Infect Dis 11:190-207. 2011
    ..We aimed to synthesise data from national surveys about these interventions, accounting for disparities in malaria risk within national borders...
  5. ncbi Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi
    James G Kublin
    Malaria Section, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
    J Infect Dis 187:1870-5. 2003
    ..The reintroduction of chloroquine, ideally in combination with another antimalarial drug, should be considered in areas where chloroquine resistance has declined and safe and affordable alternatives remain unavailable...
  6. pmc Improved diagnostic testing and malaria treatment practices in Zambia
    Davidson H Hamer
    Center for International Health and Development, Boston University School of Public Health, Boston, Mass 02118, USA
    JAMA 297:2227-31. 2007
    ....
  7. pmc Community case management of fever due to malaria and pneumonia in children under five in Zambia: a cluster randomized controlled trial
    Kojo Yeboah-Antwi
    Center for Global Health and Development, Boston University School of Public Health, Boston, Massachusetts, United States of America
    PLoS Med 7:e1000340. 2010
    ..This study was designed to assess the effectiveness and feasibility of using CHWs to manage nonsevere pneumonia and uncomplicated malaria with the aid of rapid diagnostic tests (RDTs)...
  8. pmc Options for the delivery of intermittent preventive treatment for malaria to children: a community randomised trial
    Margaret Kweku
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS ONE 4:e7256. 2009
    ..We have evaluated the coverage of IPTc that can be achieved by two different delivery systems in Ghana...
  9. pmc Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania
    Oliver J Sabot
    Malaria Control Team, Clinton Foundation HIV AIDS Initiative, Boston, Massachusetts, USA
    PLoS ONE 4:e6857. 2009
    ..To overcome this challenge, a global ACT subsidy has been proposed. We tested this proposal through a pilot program in rural Tanzania...
  10. ncbi Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures
    Jayanta Debnath
    Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
    Methods 30:256-68. 2003
    ....
  11. ncbi Drug combinations with quercetin: doxorubicin plus quercetin in human breast cancer cells
    Davide Staedler
    Centre Hospitalier Universitaire Vaudois CHUV and University of Lausanne UNIL, Lausanne, Switzerland
    Cancer Chemother Pharmacol 68:1161-72. 2011
    ..In this work, we evaluated whether the plant-derived flavonoid quercetin may represent such an agent...
  12. pmc Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
    M R Law
    Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London EC1M 6BQ
    BMJ 326:1427. 2003
    ....
  13. pmc Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali
    Alassane Dicko
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine Pharmacy and Dentistry, University of Bamako, PO Box 1805 Bamako, Mali
    Malar J 9:9. 2010
    ..However, there is a fear that IPTi may result in a rapid increase of parasite resistance to SP...
  14. pmc Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial
    Amadou T Konate
    Centre National de Recherche et de Formation sur Paludisme, Ouagadougou, Burkina Faso
    PLoS Med 8:e1000408. 2011
    ....
  15. pmc High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581
    Samwel Gesase
    National Institute for Medical Research, Tanga Centre, Tanga, Tanzania
    PLoS ONE 4:e4569. 2009
    ..This study compared the in vivo efficacy of SP in symptomatic 6-59 month children with uncomplicated malaria and in asymptomatic 2-10 month old infants...
  16. pmc Chloroquine resistance before and after its withdrawal in Kenya
    Leah Mwai
    Kenya Medical Research Institute Wellcome Trust Collaborative Research Programme, Kilifi, Kenya
    Malar J 8:106. 2009
    ..Changes to those that occurred in the dihydrofolate reductase gene (dhfr) that confers resistance to the replacement drug, pyrimethamine/sulphadoxine were also compared...
  17. pmc Impact of intermittent preventive treatment with sulphadoxine-pyrimethamine targeting the transmission season on the incidence of clinical malaria in children in Mali
    Alassane Dicko
    Malaria Research and Training Center, Departments of Epidemiology of Parasitic Diseases, Faculty of Medicine Pharmacy and Dentistry, University of Bamako, P O Box 1805, Bamako, Mali
    Malar J 7:123. 2008
    ..However in most areas malaria morbidity and mortality remain high in older children...
  18. pmc Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs
    Teun Bousema
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    Malar J 9:136. 2010
    ..Simple mathematical models were fitted to data from clinical trials in order to determine the mean gametocyte circulation time and duration of gametocyte carriage in treated malaria patients...
  19. ncbi Antibacterial activity of two MTA-based root canal sealers
    R D Morgental
    Department of Endodontics, School of Dentistry, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil
    Int Endod J 44:1128-33. 2011
    ..To evaluate the pH and antibacterial activity of Endo CPM Sealer and MTA Fillapex by two different methods, using white MTA and Endofill as references for comparison...
  20. ncbi Effect of malaria rapid diagnostic tests on the management of uncomplicated malaria with artemether-lumefantrine in Kenya: a cluster randomized trial
    Jacek Skarbinski
    Malaria Branch, US Centers for Disease Control and Prevention, Atlanta, Georgia 30341 3724, USA
    Am J Trop Med Hyg 80:919-26. 2009
    ..30). RDTs could potentially improve malaria case management, but we urgently need to develop more effective strategies for implementing guidelines before large scale implementation...
  21. ncbi Matrigel: basement membrane matrix with biological activity
    Hynda K Kleinman
    NIH, NIDCR, 30 433, 30 Convent Dr MSC 4370, Bethesda, MD 20892 4370, USA
    Semin Cancer Biol 15:378-86. 2005
    ..In vivo, it is used for measuring angiogenic inhibitors and stimulators, to improve graft survival, repair damaged tissues, and increase tumor growth...
  22. pmc Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine
    Allen L Malisa
    Department of Biological Sciences, Faculty of Science, Sokoine University of Agriculture, SUA, PO Box 3038, Morogoro, Tanzania
    Malar J 9:190. 2010
    ..These models show that where the basis of resistance is multigenic, the effects of selection can be moderated by high recombination rates, which disrupt the associations between co-selected resistance genes...
  23. pmc Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance
    Whitney E Harrington
    Malaria Program, Seattle Biomedical Research Institute, Seattle, Washington, USA
    Clin Infect Dis 53:224-30. 2011
    ..However, parasites resistant to SP are widespread in parts of Africa, and IPTp may perversely exacerbate placental infections that contain SP-resistant parasites...
  24. pmc In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa
    Christin Sisowath
    Infectious Diseases Unit, Department of Medicine and Karolinska Institutet, Stockholm, Sweden
    J Infect Dis 199:750-7. 2009
    ..Identification of drug-specific parasite determinants that contribute to treatment failures will provide important tools for the detection and surveillance of AL resistance...
  25. ncbi Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children
    Emmanuel Arinaitwe
    Makerere University University of California San Francisco Research Collaboration, University of California, San Francisco 94143, USA
    Clin Infect Dis 49:1629-37. 2009
    ..However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children...
  26. pmc Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya
    Andrew Nyandigisi
    Division of Malaria Control, Ministry of Public Health and Sanitation, Nairobi, Kenya
    PLoS ONE 6:e24781. 2011
    ..We evaluated changes in health systems and case-management indicators between the baseline survey undertaken before implementation of the policy and the follow-up survey following the first year of the implementation activities...
  27. ncbi Return of chloroquine antimalarial efficacy in Malawi
    Miriam K Laufer
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    N Engl J Med 355:1959-66. 2006
    ..The molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence and was undetectable by 2001, suggesting that chloroquine might once again be effective in Malawi...
  28. pmc Intermittent preventive treatment of malaria during pregnancy: a qualitative study of knowledge, attitudes and practices of district health managers, antenatal care staff and pregnant women in Korogwe District, North-Eastern Tanzania
    Godfrey Mubyazi
    National Institute for Medical Research, Ubwari Research Station, P O Box 81, Muheza, Tanzania
    Malar J 4:31. 2005
    ..This study assesses the knowledge, attitudes and practices of these groups in relation to malaria control with emphasis on IPTp services...
  29. pmc Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya
    D Zurovac
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Nairobi, Kenya
    Trop Med Int Health 13:99-107. 2008
    ..To describe the quality of outpatient paediatric malaria case-management approximately 4-6 months after artemether-lumefantrine (AL) replaced sulfadoxine-pyrimethamine (SP) as the nationally recommended first-line therapy in Kenya...
  30. ncbi Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali
    Abdoulaye A Djimde
    Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Odonto Stomatology, University of Bamako, Bamako, Mali
    Am J Trop Med Hyg 78:455-61. 2008
    ..The ACTs were efficacious and safe, but the selection of markers for resistance to the partner drugs raises concerns over their lifespan in areas of intense malaria transmission...
  31. pmc Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment
    W E Harrington
    Seattle Biomedical Research Institute, 307 Westlake Avenue N, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 106:9027-32. 2009
    ..Use of partially effective anti-malarial agents for IPTp may exacerbate malaria infections in the setting of widespread drug resistance...
  32. pmc Malaria drug shortages in Kenya: a major failure to provide access to effective treatment
    Beth B Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Programme Nairobi, Kenya
    Am J Trop Med Hyg 80:737-8. 2009
    ..The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the current shortcomings facing antimalarial drug supply to the public sector...
  33. pmc Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
    Christine R Jenkins
    Woolcock Institute of Medical Research, Sydney, Australia
    Respir Res 10:59. 2009
    ..However, there are only limited data about the influence of GOLD severity staging on the effectiveness of SFC, particularly in patients with milder disease...
  34. ncbi Reaching the Abuja target for intermittent preventive treatment of malaria in pregnancy in African women: a review of progress and operational challenges
    Jenny Hill
    Child and Reproductive Health Group, Liverpool School of Tropical Medicine, Liverpool, UK
    Trop Med Int Health 11:409-18. 2006
    ....
  35. pmc The ACTwatch project: methods to describe anti-malarial markets in seven countries
    Tanya Shewchuk
    Malaria and Child Survival Department, Population Services International, P, O, Box 43640 00800, Nairobi, Kenya, Africa
    Malar J 10:325. 2011
    ..The project is designed to provide a comprehensive picture of the anti-malarial market to inform national and international anti-malarial drug policy decision-making...
  36. ncbi Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi
    Kimberly E Mace
    Division of Parasitic Diseases and Malaria, Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    Clin Infect Dis 53:772-9. 2011
    ..Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation...
  37. pmc Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast
    Steffen Borrmann
    Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya
    PLoS ONE 6:e26005. 2011
    ..The emergence of artemisinin-resistant P. falciparum malaria in South-East Asia highlights the need for continued global surveillance of the efficacy of artemisinin-based combination therapies...
  38. ncbi Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
    Kishore M Gadde
    Obesity Clinical Trials Programme, Duke University Medical Center, Durham, NC 27710, USA
    Lancet 377:1341-52. 2011
    ....
  39. pmc Drug resistance maps to guide intermittent preventive treatment of malaria in African infants
    Inbarani Naidoo
    London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Parasitology 138:1469-79. 2011
    ..There are clear deficiencies in molecular surveillance data coverage. We discuss requirements for ongoing surveillance of SP resistance markers in support of the use of SP-IPTi...
  40. ncbi Recombinant vitronectin is a functionally defined substrate that supports human embryonic stem cell self-renewal via alphavbeta5 integrin
    Stefan R Braam
    Leiden University Medical Centre, Postal Zone S 1 P, P O Box 9600, 2300 RC Leiden, The Netherlands
    Stem Cells 26:2257-65. 2008
    ..Recombinant vitronectin was the only defined functional alternative to Matrigel, supporting sustained self-renewal and pluripotency in three independent hESC lines...
  41. pmc Changes in health workers' malaria diagnosis and treatment practices in Kenya
    Elizabeth Juma
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, PO Box 43640, 00100 GPO, Nairobi, Kenya
    Malar J 10:1. 2011
    ..Three years after the policy implementation, health workers' adherence to malaria diagnosis and treatment recommendations was evaluated...
  42. pmc Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial
    Jean Louis A Ndiaye
    Department of Medical Parasitology, Medical Faculty, Universite Cheikh Anta Diop, Dakar, Senegal
    Malar J 10:237. 2011
    ....
  43. pmc The impact of retail-sector delivery of artemether-lumefantrine on malaria treatment of children under five in Kenya: a cluster randomized controlled trial
    Beth P Kangwana
    Malaria Public Health and Epidemiology Group, Kenya Medical Research Institute Wellcome Trust Research Programme, Kenya
    PLoS Med 8:e1000437. 2011
    ..This study in western Kenya aimed to evaluate the impact of providing subsidized artemether-lumefantrine (AL) through retail providers on the coverage of prompt, effective antimalarial treatment for febrile children aged 3-59 months...
  44. ncbi Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
    Ting Chao Chou
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Pharmacol Rev 58:621-81. 2006
    ....
  45. pmc Health worker performance in the management of paediatric fevers following in-service training and exposure to job aids in Kenya
    Beatrice Wasunna
    Malaria Public Health and Epidemiology Group, KEMRI Wellcome Trust Research Programme, Centre for Geographic Medicine Research Coast CGMRC, Nairobi, Kenya Nairobi, Kenya
    Malar J 9:261. 2010
    ..In 2007, a new initiative was launched in one part of Kenya to improve malaria case-management through enhanced in-service training and provision of job aids...
  46. pmc SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology
    Jim Barrington
    SMS for Life Program Director, Forum 1 P 94, Novartis Campus, CH 4056 Basel, Switzerland
    Malar J 9:298. 2010
    ..Lack of visibility of anti-malarial stock levels at the health facility level is an important contributor to this problem...
  47. pmc A strategy to reduce cardiovascular disease by more than 80%
    N J Wald
    Department of Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Barts and The London, Queen Mary s School of Medicine and Dentistry, University of London, London EC1M 6BQ
    BMJ 326:1419. 2003
    ..The strategy was to simultaneously reduce four cardiovascular risk factors (low density lipoprotein cholesterol, blood pressure, serum homocysteine, and platelet function) regardless of pretreatment levels...
  48. pmc Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomised controlled non-inferiority trial
    Harry Tagbor
    Department of Community Health, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
    PLoS ONE 5:e14425. 2010
    ..Therefore, we have investigated whether screening with a rapid diagnostic test and treatment of those who are positive (IST) at routine antenatal clinic attendances is as effective and as safe as SP-IPTp in pregnant women...
  49. ncbi Mineral trioxide aggregate: a comprehensive literature review--part II: leakage and biocompatibility investigations
    Mahmoud Torabinejad
    Endodontic Residency Program, Department of Endodontics, School of Dentistry, Loma Linda University, Loma Linda, California 92350, USA
    J Endod 36:190-202. 2010
    ..The purpose of part II of this review is to present a comprehensive list of articles regarding the sealing ability and biocompatibility of this material...
  50. ncbi Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal
    Babacar Faye
    Department of Parasitology, Faculty of de Medicine, Cheikh Anta Diop University of Dakar, Dakar, Senegal
    Parasitol Res 109:133-8. 2011
    ..This study reveals that despite an increase in the prevalence of individual mutations, the IPT-SP coupled with the EPI has no major impact on DHFR and DHPS combined mutations...
  51. ncbi Hydration mechanisms of mineral trioxide aggregate
    J Camilleri
    Department of Building and Civil Engineering, Faculty of Architecture and Civil Engineering, University of Malta, Msida, Malta
    Int Endod J 40:462-70. 2007
    ..To report the hydration mechanism of white mineral trioxide aggregate (White MTA, Dentsply, Tulsa Dental Products, Tulsa, OK, USA)...
  52. ncbi Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
    J Clin Oncol 28:1547-53. 2010
    ..Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage...
  53. ncbi Physicochemical basis of the biologic properties of mineral trioxide aggregate
    N K Sarkar
    Operative Dentistry and Biomaterials Department, LSU, School of Dentistry, 1100 Florida Ave, New Orleans, LA 70119, USA
    J Endod 31:97-100. 2005
    ..The dentin-mineral trioxide aggregate interfacial layer results from a similar reaction. The sealing ability, biocompatibility, and dentinogenic activity of mineral trioxide aggregate is attributed to these physicochemical reactions...
  54. pmc Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites
    IkeOluwapo O Ajayi
    Malaria Research Laboratories, Institute of Medical Research and Training, College of Medicine, University of Ibadan, Nigeria
    Malar J 7:6. 2008
    ..The feasibility and acceptability of incorporating ACT in HMM needs to be evaluated...
  55. ncbi Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis
    Ajay K Gupta
    International Centre for Circulatory Health, Imperial College London, London, United Kingdom
    Hypertension 55:399-407. 2010
    ..21 [95% CI: 1.03 to 1.43]; P=0.02) compared with its corresponding free-drug combinations. In 3 cohort studies (n=12 653), there was a nonsignificant improvement in persistence with therapy (odds ..
  56. pmc Antimalarial drug resistance of Plasmodium falciparum in India: changes over time and space
    Naman K Shah
    Department of Epidemiology, University of North Carolina, Chapel Hill, USA
    Lancet Infect Dis 11:57-64. 2011
    ..Strategies to reduce the emergence and spread of future drug resistance need to be proactive and supported by intensive monitoring...
  57. pmc The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa
    Lesong Conteh
    Swiss Tropical and Public Health Institute, Basel, Switzerland
    PLoS ONE 5:e10313. 2010
    ..To date, there have been limited data on the cost-effectiveness of this strategy using sulfadoxine pyrimethamine (SP) and no published data on cost-effectiveness using other antimalarials...
  58. pmc Effectiveness of antenatal clinics to deliver intermittent preventive treatment and insecticide treated nets for the control of malaria in pregnancy in Kenya
    Jenny Hill
    Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
    PLoS ONE 8:e64913. 2013
    ..We analysed household survey data to evaluate the effectiveness of antenatal clinics (ANC) to deliver IPTp and ITNs to pregnant women in Nyando district, Kenya...
  59. pmc Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis
    Julien Zwang
    Shoklo Malaria Research Unit, Mae Sot, Thailand
    Malar J 8:203. 2009
    ..It was necessary to evaluate the efficacy of ACT, recently adopted by the World Health Organization (WHO) and deployed over 80 countries, in order to make an evidence-based drug policy...
  60. pmc Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study
    Steve M Taylor
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, 27599, USA
    Clin Infect Dis 55:42-50. 2012
    ..Recent studies report that drug resistance may cause IPTp-SP to exacerbate PAM morbidity, raising fears that current policies will cause harm as resistance spreads...
  61. ncbi Mineral trioxide aggregate: a comprehensive literature review--Part I: chemical, physical, and antibacterial properties
    Masoud Parirokh
    Department of Endodontics, School of Dentistry, Oral and Dental Diseases Research Center, Neuroscience Research Center, Iranian Center for Endodontic Research, Kerman University of Medical Sciences, Kerman, Iran
    J Endod 36:16-27. 2010
    ..The aim of Part I of this literature review is to present investigations regarding the chemical, physical, and antibacterial properties of MTA...
  62. pmc Feasibility and acceptability of home-based management of malaria strategy adapted to Sudan's conditions using artemisinin-based combination therapy and rapid diagnostic test
    Khalid A Elmardi
    National Malaria Control Programme, Federal Ministry of Health, Khartoum, Sudan
    Malar J 8:39. 2009
    ..This research aimed to assess the feasibility and acceptability of home-based management of malaria (HMM) strategy using artemisinin-based combination therapy (ACT) for treatment and rapid diagnostic test (RDT) for diagnosis...
  63. ncbi Pyronaridine-artesunate versus mefloquine plus artesunate for malaria
    Ronnatrai Rueangweerayut
    Department of Internal Medicine, Mae Sot General Hospital, Tak, Thailand
    N Engl J Med 366:1298-309. 2012
    ..Pyronaridine-artesunate is an artemisinin-based combination therapy under evaluation for the treatment of Plasmodium falciparum and P. vivax malaria...
  64. ncbi Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial
    Antoinette K Tshefu
    Ecole de Santé Publique, Faculte de Medecine, Universite de Kinshasa, Kinshasa, Democratic Republic of the Congo
    Lancet 375:1457-67. 2010
    ..We compared the efficacy and safety of pyronaridine-artesunate with that of artemether-lumefantrine for treatment of uncomplicated P falciparum malaria...
  65. pmc Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children
    Michael Nambozi
    Department of Clinical Sciences, Tropical Disease Research Center, P, O Box 71769, Ndola Zambia
    Malar J 10:50. 2011
    ..In 2002, the first-line treatment for uncomplicated malaria was changed to artemether-lumefantrine (AL) that has proved to be highly efficacious against multidrug resistant Plasmodium falciparum...
  66. pmc Quality of malaria case management at outpatient health facilities in Angola
    Alexander K Rowe
    Centers for Disease Control and Prevention, Atlanta, USA
    Malar J 8:275. 2009
    ..Implementation was complicated by a policy that was sometimes ambiguous...
  67. pmc Two strategies for the delivery of IPTc in an area of seasonal malaria transmission in the Gambia: a randomised controlled trial
    Kalifa A Bojang
    Medical Research Council Laboratories, Banjul, The Gambia
    PLoS Med 8:e1000409. 2011
    ..In rural areas, RCH trekking teams provide most of the health care to children under the age of 5 years in the Infant Welfare Clinic, and provide antenatal care for pregnant women...
  68. pmc Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria
    Catherine O Falade
    Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria
    Malar J 6:88. 2007
    ..This study sets out to evaluate the effectiveness of IPT-SP in the prevention of maternal and placental malaria in parturient mothers in Ibadan, Nigeria, where the risk of malaria is present all year round...
  69. pmc Cost effectiveness of seasonal intermittent preventive treatment using amodiaquine & artesunate or sulphadoxine-pyrimethamine in Ghanaian children
    Lesong Conteh
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS ONE 5:e12223. 2010
    ..It is important to determine the costs associated with IPTc delivery via community based volunteers and also the potential savings to health care providers and caretakers due to malaria episodes averted as a consequence of IPTc...
  70. ncbi Effect of pH on sealing ability of white mineral trioxide aggregate as a root-end filling material
    Mohammad Ali Saghiri
    Department of Biomedical Engineering, Islamic Azad University, Tehran, Iran
    J Endod 34:1226-9. 2008
    ..4 followed by pH values of 5.4, 6.4, and 7.4, respectively. There was a significantly longer time necessary for leakage to occur in samples stored in higher pH values (P < .000)...
  71. pmc Prediction of drug combinations by integrating molecular and pharmacological data
    Xing Ming Zhao
    European Molecular Biology Laboratory EMBL, Heidelberg, Germany
    PLoS Comput Biol 7:e1002323. 2011
    ..However, screening new drug combinations exhaustively is impractical considering all possible combinations between drugs...
  72. ncbi Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study
    Hans Jurgen Stellbrink
    Infektions Medizinisches Centrum Hamburg Study Center, Hamburg, Germany
    Clin Infect Dis 51:963-72. 2010
    ..Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles...
  73. ncbi Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study
    Frank A Post
    King s College London, London, United Kingdom
    J Acquir Immune Defic Syndr 55:49-57. 2010
    ..Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are commonly used first-line antiretroviral therapies, yet few studies have comprehensively compared their safety profiles...
  74. pmc Prevalence of resistance associated polymorphisms in Plasmodium falciparum field isolates from southern Pakistan
    Najia Karim Ghanchi
    Malaria Research Lab, Infectious Diseases Unit, Department of Medicine, Karolinska University Hospital Karolinska Institutet, Retziusväg 10, Stockholm, Sweden
    Malar J 10:18. 2011
    ..The aim of this study was, therefore, to determine the prevalence of P. falciparum resistance associated polymorphisms in field isolates from southern Pakistan...
  75. ncbi Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    Narikazu Boku
    Shizuoka Cancer Centre, Shizuoka, Japan
    Lancet Oncol 10:1063-9. 2009
    ..We aimed to investigate the superiority of irinotecan plus cisplatin and non-inferiority of S-1 compared with fluorouracil, with respect to overall survival, in patients with metastatic gastric cancer...
  76. pmc A pharmacy too far? Equity and spatial distribution of outcomes in the delivery of subsidized artemisinin-based combination therapies through private drug shops
    Justin M Cohen
    Clinton Health Access Initiative, 383 Dorchester Ave, Boston MA, 02127, USA
    BMC Health Serv Res 10:S6. 2010
    ..The Government of Tanzania and the Clinton Foundation piloted this subsidized distribution model in two Tanzanian districts to examine concerns about whether the intervention will successfully reach poor, rural communities...
  77. pmc Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective
    Sandra Alba
    Dept Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Malar J 9:164. 2010
    ..Subsidized ALu was made available in both health facilities and ADDOs. The effect of these interventions on access to malaria treatment was studied in rural Tanzania...
  78. ncbi Deploying artemether-lumefantrine with rapid testing in Ethiopian communities: impact on malaria morbidity, mortality and healthcare resources
    Hailemariam Lemma
    Tigray Health Bureau, Mekelle, Ethiopia
    Trop Med Int Health 15:241-50. 2010
    ....
  79. ncbi Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
    Patrice Piola
    Epicentre, Paris, France
    Lancet Infect Dis 10:762-9. 2010
    ..We aimed to assess whether artemether-lumefantrine was at least as efficacious as oral quinine for the treatment of uncomplicated falciparum malaria during the second and third trimesters of pregnancy in Mbarara, Uganda...
  80. pmc Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya
    J Teun Bousema
    Department of Medical Microbiology, University Medical Centre, Nijmegen, The Netherlands
    Malar J 3:18. 2004
    ..This study identified factors that influence gametocytaemia in asymptomatic children in the absence and presence of pyrimethamine-sulphadoxine (SP) antimalarial treatment...
  81. ncbi Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection
    Jaap T van Dissel
    Leiden University Medical Center LUMC, Department of Infectious Diseases, Leiden, The Netherlands j t van
    Vaccine 29:2100-9. 2011
    ..The strong responses persisted through 32 weeks of follow-up, indicating the induction of a persistent memory response in the vaccine recipients...
  82. ncbi Multi-target therapeutics: when the whole is greater than the sum of the parts
    Grant R Zimmermann
    CombinatoRx Inc, 245 First Street, Cambridge, MA 02142, USA
    Drug Discov Today 12:34-42. 2007
    ....
  83. ncbi Feeder-free growth of undifferentiated human embryonic stem cells
    C Xu
    Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025, USA
    Nat Biotechnol 19:971-4. 2001
    ..Thus, the cells retain fundamental characteristics of hES cells in this culture system and are suitable for scaleup production...
  84. pmc Knowledge of malaria influences the use of insecticide treated nets but not intermittent presumptive treatment by pregnant women in Tanzania
    Rhoida Y Nganda
    Kilimanjaro Christian Medical Centre, PO Box 3010, Moshi, Tanzania
    Malar J 3:42. 2004
    ..This study explores the determinants of uptake for both ITNs and IPTp-SP by pregnant women and the role that individual knowledge and socio-economic status has to play for each...
  85. ncbi Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy
    M M Nyunt
    Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Clin Pharmacol Ther 87:226-34. 2010
    ....
  86. ncbi Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis
    Erik Sahai
    Cancer Research UK Centre for Cell and Molecular Biology, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Nat Cell Biol 5:711-9. 2003
    ..Combined blockade of extracellular proteases and ROCK negates the ability of tumour cells to switch between modes of motility and synergises to prevent tumour cell invasion...
  87. pmc Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania
    Abdunoor M Kabanywanyi
    Ifakara Health Institute, P, O, Box 78373, Kiko Avenue, Old Bagamoyo Road, Mikocheni, Dar es Salaam, Tanzania
    Malar J 9:48. 2010
    ..Controlled clinical trials have shown that a six-dose regimen of artemether-lumefantrine (AL) therapy for uncomplicated Plasmodium falciparum malaria results in cure rates >95% with good tolerability...
  88. pmc Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia
    Karen I Barnes
    Division of Clinical Pharmacology, Department of Medicine, University of Cape Town Faculty of Health Sciences, Anzio Road, Observatory, 7925, South Africa
    Malar J 8:S8. 2009
    ..Artemisinin-based combination therapy has made a substantial contribution to reducing the burden of malaria in sub-Saharan Africa...
  89. pmc Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine
    Nahla B Gadalla
    Department of Epidemiology, Tropical Medicine Research Institute, National Centre for Research, Khartoum, Sudan
    Antimicrob Agents Chemother 55:5408-11. 2011
    ..One individual carried parasites with a novel pfmdr1 polymorphism (F1044L). pfmdr1 gene amplification in parasites prior to treatment occurred in three individuals who had recurrent infection during follow-up...
  90. pmc Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria
    Richard T Eastman
    Department of Microbiology and Immunology, Columbia University College of Physicians and Surgeons, Hammer Health Sciences Center, Room 1502, 701 West 168th Street, New York 10032, New York, USA
    Nat Rev Microbiol 7:864-74. 2009
    ..This Review article discusses our current knowledge about the mode of action of ACTs, their pharmacological properties and the proposed mechanisms of drug resistance...
  91. ncbi Rat tissue reaction to MTA FILLAPEX®
    João Eduardo Gomes-Filho
    Department of Endodontics, Araçatuba School of Dentistry, University of Estadual Paulista, R Jose Bonifacio 1193, Aracatuba, Sao Paulo, Brazil
    Dent Traumatol 28:452-6. 2012
    ..Mineralization and granulation birefringent to polarized light were observed with all materials. It was concluded that MTA FILLAPEX® was biocompatible and stimulated mineralization...
  92. ncbi Use of antenatal care services and intermittent preventive treatment for malaria among pregnant women in Blantyre District, Malawi
    Timothy H Holtz
    Malaria Epidemiology Branch, Division of Parasitic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Trop Med Int Health 9:77-82. 2004
    ..2, 95% CI 1.02-1.5, P=0.03). A substantial effort to improve the delivery and use of SP/IPT in Malawi will be necessary, but the Roll Back Malaria 2005 goal appears achievable...
  93. ncbi Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine
    Takashi Sasaki
    Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 8655, Japan
    Invest New Drugs 30:708-13. 2012
    ..The most common non-hematological toxicities were nausea (27%), anorexia (55%), and pigmentation (32%). In conclusion, S-1 monotherapy is feasible and moderately efficacious second-line chemotherapy for advanced BTC...
  94. pmc Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia
    Pharath Lim
    Institut Pasteur in Cambodia, Phnom Penh, Cambodia
    Malar J 8:11. 2009
    ....
  95. ncbi A multiparametric assay to compare the cytotoxicity of endodontic sealers with primary human osteoblasts
    M Z Scelza
    Laboratory of Experimental Cell Culture, Department of Endodontics, Fluminense Federal University UFF, Niteroi, RJ Brazil
    Int Endod J 45:12-8. 2012
    ....
  96. pmc Determinants of use of intermittent preventive treatment of malaria in pregnancy: Jinja, Uganda
    Laura R Sangaré
    Department of Global Health, University of Washington, Seattle, Washington, USA
    PLoS ONE 5:e15066. 2010
    ..Additionally, we characterized the timing of and indications for the administration of SP at antenatal care (ANC) visits and missed opportunities for SP administration...
  97. ncbi Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial
    Billy E Ngasala
    Malaria Research, Infectious Diseases Unit, Department of Medicine Solna, Karolinska University Hospital, Stockholm, Sweden
    Clin Infect Dis 52:873-82. 2011
    ....
  98. pmc An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data
    Guangxu Jin
    Systems Medicine and Bioengineering Department, Cornell University, Houston, TX 77030, USA
    Bioinformatics 27:i310-6. 2011
    Prediction of synergistic effects of drug combinations has traditionally been relied on phenotypic response data. However, such methods cannot be used to identify molecular signaling mechanisms of synergistic drug combinations...
  99. pmc Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial
    Stephen I Rennard
    Pulmonary Critical Care, Allergy and Sleep Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198 5885, USA
    Drugs 69:549-65. 2009
    ....
  100. pmc Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi
    David J Bell
    Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool L7 8XP, UK
    Malar J 8:204. 2009
    ..The aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD...
  101. pmc Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia
    Ambachew M Yohannes
    World Health Organization Country Office, Addis Ababa, Ethiopia
    Am J Trop Med Hyg 84:137-40. 2011
    ..6%) for AL was detected. CQ resistance was confirmed in three of five CQ treatment failures cases. The effectiveness of AL seems lower than CQ; however, the findings were not conclusive, because the AL evening doses were not supervised...

Research Grants71

  1. Na+/H+-exchanger-1 and Diabetic Neuropathy
    MARK ANTHONY YOREK; Fiscal Year: 2012
    ..of diabetes and may provide rationale for development of NHE-1 inhibitors and NHE-1 inhibitor- containing drug combinations. PUBLIC HEALTH RELEVANCE: Peripheral diabetic neuropathy (PDN) is the most devastating complication of ..
  2. Biomarkers to Assess Selenium Chemoprevention for NSCLC
    Steven A Belinsky; Fiscal Year: 2012
    ..Third, through a supplement, we evaluated drug combinations for chemoprevention...
  3. Combination therapies for chronic HBV, liver disease and cancer
    Mark A Feitelson; Fiscal Year: 2012
    ..To do so, the lab will assess the pharmacokinetics (PK), antiviral efficacy and toxicity of drug combinations in primary human hepatocytes and in HepG2 cells replicating wild type or selected mutants of HBV (aim 1)...
  4. Innovative technologies to effectively treat Multi-drug resistant and/or biofilm-
    Jie Wen; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): This Phase I project is to evaluate a series of novel drug combinations to prevent and treat wound infections...
  5. DECISION SUPPORT SYSTEM TO GUIDE PEDIATRIC PHARMACOTHERAPY
    JEFFREY SCOTT BARRETT; Fiscal Year: 2010
    ..with utilization and 4) educate physicians on clinical pharmacologic principles specific to population and drug combinations of interest. Within this system, static compendial information (e.g...
  6. Novel Antifungal Therapeutic Approaches
    Joseph Heitman; Fiscal Year: 2012
    ..of an amino biosynthetic cascade targeted by known antifungal agents and define synergistic antifungal drug combinations. Finally, drugs, analogs, and combinations will be tested in animal models of cryptococcosis and candidiasis...
  7. CELL BIOLOGY OF THE NEURONAL SODIUM CHANNEL
    William A Catterall; Fiscal Year: 2013
    ..iv) Our results indicate that rationally designed drug combinations that increase GABAergic neurotransmission are effective in reducing seizures and premature death in DS mice ..
  8. The Mycobacterium Tuberculosis Dormancy Program
    MARTIN INUA VOSKUIL; Fiscal Year: 2013
    ..Our research directly supports this goal. New antimycobacterial drugs and drug combinations are routinely tested against hypoxic/anaerobic bacilli, but questions about the proper protocol and our ..
  9. Targeting Src Signaling Pathways to Promote Cell Cycle Arrest in Ovarian Cancer
    Fiona Simpkins; Fiscal Year: 2013
    ..AIM 1 will test different Src inhibitor-drug combinations for anti-proliferative activity in an expanded series of ER positive OVCA cell lines and study the ..
  10. The population genetics of antibiotic resistance in multi-drug environments
    Roy Kishony; Fiscal Year: 2013
    ..provided by applicant): The proliferation of antibiotic-resistant pathogens has spurred the use of drug combinations to maintain clinical efficacy and combat the evolution of resistance...
  11. Firing up new treatments against Mycobacterium ulcerans disease (Buruli ulcer)
    Jacques H Grosset; Fiscal Year: 2013
    ..ulcerans, our third aim is to systematically screen for novel in vitro and in vivo active drugs and drug combinations using the new lux-containing M. ulcerans...
  12. Pharmacoepidemiology of Atypical Antipsychotic Drugs
    William V Bobo; Fiscal Year: 2013
    ..diabetes related to bipolar disorder maintenance treatment with mood stabilizer + atypical antipsychotic drug combinations vs...
  13. Genotyping and Phenotyping the Hepatitis C Drug Target NS5A
    ROBERT T STRIKER; Fiscal Year: 2011
    ..predictably effective therapy can be offered, the rising cost of HCV may be reversed, similar to what new drug combinations did for the cost of HIV care...
  14. Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
    Robert A Gatenby; Fiscal Year: 2013
    ..from the maximum tumor cell killing ("all-out attack") approach to the use of "evolutionarily enlightened" drug combinations to stabilize the tumor burden...
  15. Role of Calcineurin in Fungal Virulence
    Joseph Heitman; Fiscal Year: 2009
    ..Importantly, this pathway can be targeted for therapeutic intervention using non-immunosuppressive calcineurin inhibitors that retain antifungal activity and synergistic drug combinations that we have discovered.
  16. Targeted Radiotherapy with 90Y-BC8 Monclonal Antibody, Fludarabine and TBI Follow
    William I Bensinger; Fiscal Year: 2012
    ..conventional therapy alone have demonstrated significant improvements in survival. Novel drug combinations of thalidomide, lenalidomide and bortezomib plus ASCT have further improved progression-free survival ..
  17. Delayed Onset of Biofilm Formation and CAUTI with Superhydrophobic Catheters
    Sanjiv Lalwani; Fiscal Year: 2011
    ..prone to antimicrobial resistance development;(ii) antimicrobial- impregnated catheters using several drugs/drug combinations elicit yet-to-be-established confidence in their efficacy...
  18. Neurosteroid-BZ combinations: Strategy for reducing abuse and sedation
    James K Rowlett; Fiscal Year: 2013
    ..data will be evaluated with isobolographic/dose-addition analysis in order to determine if effects of drug combinations are additive, supra-additive, or infra-additive...
  19. Central actions of angiotensin II in the control of fluid balance
    Daniel K Yee; Fiscal Year: 2013
    ..Using these drug combinations, we will address: (1) the cellular intermediary proteins that connect the AT1 receptor to MAPK signaling, (2)..
  20. Evaluation of HIV-1 Drug Resistance among Antiretroviral Treatment Naive and Expe
    Avelin Fobang Aghokeng; Fiscal Year: 2013
    ..The CREMER Virology Laboratory is a WHO accredited reference laboratory for the surveillance of HIV-1 drug resistance. ) ..
  21. Potent Analgesic Conopeptides for Treatment of Chronic Spinal Cord Injury Pain
    Jacqueline Sagen; Fiscal Year: 2012
    ..These findings are remarkable in light of the difficulty in obtaining even modest effects of other drug combinations in this model or in clinical SCI pain reports...
  22. Rational polytherapy in the treatment of cholinergic seizures
    Claude G Wasterlain; Fiscal Year: 2013
    ..Our preliminary results suggest that such three-drug combinations can, with little depression of consciousness, stop seizures induced by high-dose lithium and pilocarpine and ..
  23. DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS
    Jianxin Bao; Fiscal Year: 2010
    ..In summary, this proposal will develop a paradigm-shifting approach to test novel drug combinations against NIHL...
  24. Identification and eradication of HIV tissue reservoirs in a relevant animal mode
    Binhua Ling; Fiscal Year: 2013
    ..the above therapy in an attempt to quantify the decay of cell and tissue reservoirs in macaques on multiple drug combinations. Further, we may design specific strategies to target specific sites using the knowledge gained in Aim1 to ..
  25. AML Stem Cell Heterogeneity: Implications for Gemtuzumab Ozogomicin-based Therapy
    Roland Walter; Fiscal Year: 2009
    ..Research will also be performed to find out which patients benefit most from these therapies and to see how these drug combinations precisely work together with GO to kill leukemia cells.
  26. Primate Model Towards HIV Eradication Strategies
    RAYMOND FELIX SCHINAZI; Fiscal Year: 2012
    ..In addition to virological endpoints, the impact of these drug combinations will be evaluated in RT-SHIV-infected resting CD4+ lymphocyte populations...
  27. B. thuringiensis Crystal Proteins as Powerful Next-Generation Anthelmintics
    Raffi V Aroian; Fiscal Year: 2013
    ..Tests of Cry5B's effectiveness alone and in drug combinations will be performed using the free-living roundworm C. elegans, the mouse parasite H...
  28. Targeted Intervention of Breast Oncogenic Pathways
    Said M Sebti; Fiscal Year: 2013
    ..Clinical trials will be performed to evaluate the efficacy of the drug combinations.
  29. DEVELOPMENT OF A DRUG THERAPY TO AMELIORATE PERMANENT HEARING LOSS
    Jianxin Bao; Fiscal Year: 2013
    ..For example, if successful, a similar approach can be explored for the treatment of presbycusis and tinnitus. In summary, this proposal will develop a paradigm-shifting approach to test novel drug combinations against NIHL.
  30. Glycemic Reduction Approaches for Treating Diabetes: An Effectiveness Study
    David M Nathan; Fiscal Year: 2011
    ..will be included with the metformin-treated stratum in the analyses of the differences among the five drug combinations. The proposed partial factorial design is an efficient way to compare the five major diabetes drug ..
  31. Mechanisms of Herpetic Keratitis
    Barry T Rouse; Fiscal Year: 2013
    ..The final Aim will be to use drug combinations that target different steps in SK pathogenesis which are expected to have improved efficacy compared to ..
  32. HBV Research Network Database Protocol and Clinical Trial Study Proposals
    TRAM THUY TRAN; Fiscal Year: 2013
    ..of nucleos(t)ide analog drugs;and 3) to measure intrahepatic cccDNA decline on the nucleos(t)ide drug combinations. For the database protocol, eAg (+) and eAg (-) chronic HBV patients will be prospectively enrolled into a ..
  33. BcL-2 Proteins in Mechanism of Anti-mitotic Drug Action
    Timothy C Chambers; Fiscal Year: 2013
    ..new drug targets can be uncovered;points of vulnerability in tumor cells versus normal cells exploited;novel drug combinations tested;and determinants of drug sensitivity revealed...
  34. Targeted Therapies for HIV-Associated Kaposi Sarcoma and Lymphoma
    Dirk P Dittmer; Fiscal Year: 2013
    ..We propose to identify drug combinations and to delineate the molecular mechanism of these therapeutics, which will serve as the next generation of ..
  35. Arizona Center for Education and Research on Therapeutics
    Raymond L Woosley; Fiscal Year: 2010
    ..human and systems factors responsible for the co-prescription, co-dispensing and co-administration of drug combinations that have the potential to interact (PDDIs) and cause ADDRs...
  36. TOPOISOMERASE I INHIBITORS IN LEUKEMIA AND SOLID TUMORS
    Scott H Kaufmann; Fiscal Year: 2010
    ..Finally, in preclinical studies examining drug combinations, we showed that topo I poisons synergize with the epidermal growth factor receptor tyrosine kinase inhibitor ..
  37. Novel approaches to develop a treatment for cryptosporidiosis
    Christopher D Huston; Fiscal Year: 2013
    ..Synergistic drug combinations sometimes possess cidal antimicrobial activity (i.e...
  38. Regulation of Vascular Smooth Muscle Cell Proliferation
    Hana Totary Jain; Fiscal Year: 2010
    ..We will test new drug combinations in animal model in which resistance to rapamycin's antiproliferative effect was observed.
  39. A Phase II proof-of-concept trial to study kinase inhibition in relapsed/refracto
    MARC MAURICE LORIAUX; Fiscal Year: 2012
    ..of individualized kinase therapy and apply this information to enhance development of new drugs and new drug combinations in leukemia patients...
  40. Cell Biology of Vasopressin-Induced Water Channels
    Dennis Brown; Fiscal Year: 2013
    ..We will optimize treatment doses, times and delivery routes, and assess the effectiveness of drug combinations. Then, we will further develop our new chemical screening program to identify and characterize compounds ..
  41. Stem cell mediated targeting of tumor cells and associated vasculature in gliomas
    Khalid A Shah; Fiscal Year: 2013
    ..have raised fundamental questions about modes of delivery and the types of anti-angiogenic and cytotoxic drug combinations used to 1) normalize tumor vasculature;and 2) enhance the outcome of cytotoxic therapy post-normalization ..
  42. Exploiting Biological Networks to Improve Clinical Treatment of Ovarian Cancer
    Andrew K Godwin; Fiscal Year: 2013
    ..studies to identify productive targets of co-inhibition, with the ultimate goal of identifying new drug combinations that will greatly enhance the treatment of women with EOC...
  43. Malaria Evolution in South Asia
    Pradipsinh K Rathod; Fiscal Year: 2013
    ..While deployment of insecticide impregnated bed nets, new drug combinations, and possibly new vaccines may help control malaria, we hypothesize that shrinking parasite population sizes ..
  44. TOR kinase inhibitors for leukemia therapy: mechanisms of action and resistance
    David A Fruman; Fiscal Year: 2013
    ..We will then test combination strategies in vitro and in vivo. Identifying mechanisms of resistance and applying appropriate drug combinations will broaden the potential application of active-site TOR inhibitors.
  45. Functions of Regulatory Motifs in Signaling Networks
    SRINIVAS RAVI V IYENGAR; Fiscal Year: 2013
    ..dependent deep control at the level of subcellular functions will allow us to identify drug targets and drug combinations that can be used to obtain restoration of function by axon regeneration after injury...
  46. Combinations of FDA-Approved Host-Targeted Drugs with Broad Antiviral Activity
    JACK THANH NGUYEN; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The goal of this project is the development of antiviral drug combinations composed of FDA-approved host- targeted compounds as therapeutic regimens with enhanced potency, broad-spectrum activity and ..
  47. Sideport Needle Array Technologies for Prioritizing Drugs for Cancer Patients
    James M Olson; Fiscal Year: 2012
    ..We have developed technologies that enable oncology drug sensitivity/resistance testing of multiple drugs or drug combinations in vivo during the days prior to surgical resection of a tumor...
  48. Molecular Targets in T Lineage Leukemia
    Monique Dail; Fiscal Year: 2012
    ..During the independent phase I will evaluate and validate resistance to drug combinations, validate molecules/pathways that substitute for active Notch1, and test therapies directed at novel drug ..
  49. Molecular Targeting Strategies in HNSCC
    Daniel E Johnson; Fiscal Year: 2013
    ..We also expect that our results will guide the design of novel treatment strategies and provide the basis for clinical evaluation of synergistic drug combinations in HNSCC.
  50. PHASE I CLINICAL TRIALS OF ANTICANCER AGENTS
    Charles Erlichman; Fiscal Year: 2013
    ..Studies of drug combinations will be designed based on preclinical data identifying the appropriate schedule and exposure duration of the ..
  51. Comparative Pharmaco-oncogenomics of Myeloma Drug Resistance
    Peter Leif Bergsagel; Fiscal Year: 2013
    ..We will use response rate and time to progression in Vk*MYC MM to study in vivo drug combinations with proteasome inhibitors, seeking pre-clinical evidence of synergy in this model to support its use for ..
  52. Dual Function Acridones as A New Antimalarial Chemotype
    Jane X Kelly; Fiscal Year: 2010
    ..It represents a novel strategy to expand, enhance, and sustain effective antimalarial drug combinations. The ability to enhance the efficacy of newer drugs (e.g...
  53. Identification of the anti-neoplastic target of bioactive FTY720 analogs
    Stephen Hanessian; Fiscal Year: 2013
    ..mechanisms of resistance to these drugs, 3) anticipate potential toxicities, 4) make predictions about drug combinations that are likely to be synergistic, and 5) test our model for how these compounds selectively kill cancer ..
  54. Pharmacodynamic modeling of antibiotics on cystic fibrosis P. aeruginosa biofilms
    Katherine Y Yang; Fiscal Year: 2013
    ..aeruginosa biofilms and will enable the discovery of alternative antimicrobial dosing strategies and drug combinations specifically targeting P. aeruginosa biofilms in CF with the ultimate goal of improving clinical care...
  55. Mechanisms of Herceptin resistance
    Rita Nahta; Fiscal Year: 2013
    ..Ultimately, this study will benefit human health by identifying new molecular targets, novel drug combinations, and molecular markers of drug resistance in HER2-overexpressing breast cancer...
  56. Sputum M. tuberculosis DNA Kinetics During TB Treatment in Patients with HIV
    CHARLES KNOX EVERETT; Fiscal Year: 2012
    ..In addition, and perhaps more importantly, it could speed the development of more potent drug combinations that would shorten therapy. Both advances are critical to the control of the HIV and TB co-epidemics...
  57. Inhibiting VHL-positive kidney cancer
    GEORGE VICTOR THOMAS; Fiscal Year: 2013
    ..survival and tumor-specific bypass pathways in VHL-Positive RCC and leverage this insight into novel drug combinations and biomarkers for a disease that is incurable...
  58. Search Algorithms for Drug Combinations: Extending Approved Cancer Therapies
    Carlo Piermarocchi; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Search algorithms for drug combinations: Extending approved cancer therapies...
  59. Glycemia Reduction Approaches in Diabetes: A comparative effectiveness study
    David M Nathan; Fiscal Year: 2013
    ..We will also examine the phenotypic characteristics and pathophysiologic factors associated with metabolic response to and/or failure of the drug combinations.
  60. Abl Kinases in growth factor signaling, motility, and invasion
    Rina Plattner; Fiscal Year: 2011
    ..mechanistic insight into how abnormal regulation of the Abl kinases contributes to breast cancer progression, which may aid in the discovery of new drug combinations for preventing breast cancer metastasis and decreasing mortality.
  61. Drug Discovery Consortium for Chagas Disease
    Rick L Tarleton; Fiscal Year: 2010
    ..targets or a combination of new compounds with compounds currently in use will be investigated to identify drug combinations which are effective using shorter treatment periods or lower doses...
  62. Targeted Radiotherapy/Chemotherapy Treatment of Prostate Cancer
    Timothy J Hoffman; Fiscal Year: 2013
    ..accomplished using in vitro cell viability and clonogenic assays to assess cytotoxicity and synergism of the drug combinations (Docetaxel/177Lu-BB2r antagonist vs...
  63. AZITHROMYCIN TREATMENT FOR DRUG-RESISTANT MALARIA
    Jonathan Berman; Fiscal Year: 2000
    ..A series of clinical trials will be conducted to demonstrate efficacy and safety of azithromycin drug combinations for malaria, including the special, at risk populations (children and pregnant women)...
  64. CLINICAL GENE THERAPY PROGRAM FOR THE TREATMENT OF AIDS
    Rafael Amado; Fiscal Year: 2002
    ..The ability of these drug combinations to greatly suppress virus replication has raised the question as to whether complete eradication of HIV can ..
  65. Novel drug combinations for the management of pain
    KENNETH NARDUCY; Fiscal Year: 2007
    ..abstract_text> ..
  66. IN VIVO ACTIONS OF ANTIARRHYTHMIC DRUGS
    Dan Roden; Fiscal Year: 1990
    ..We will test several hypotheses based on the MRT: that certain drug combinations exert antagonistic effects on in vivo indices of sodium channel function, while others are synergistic; that ..
  67. DRUG SEQUENCING RESISTANCE IN MULTIPLE MYELOMA
    Daniel Sullivan; Fiscal Year: 1999
    ..the lack of a plateau in progression free survival after high-dose chemotherapy suggests that more effective drug combinations involving new antitumor agents are needed...
  68. MECHANISMS AND MODULATION OF ETOPOSIDE--VP-16 RESISTANCE
    Jack Yalowich; Fiscal Year: 1991
    ..These drug combinations will be used to assess cytotoxicity in: 1) VP-16 resistant, Vinca alkaloid sensitive K562 cells which have ..
  69. ABUSE LIABILITY OF DRUG ADJUNCTS FOR COCAINE WITHDRAWL
    Frank Holloway; Fiscal Year: 1992
    ..limited access cocaine self-administration task to assess the "reinforcing" properties of these duplicitous drug combinations using: (1) substitution tests, (2) preloading, and (3) progressive ratio schedules of reinforcement...
  70. Cell Survival Pathways and Inhibitors in Leukemia
    Alan Eastman; Fiscal Year: 2003
    ..survival signaling pathways, and that by defining which pathway a specific leukemia uses, effective drug combinations can be individualized for that patient...
  71. CENTRAL NERVOUS SYSTEM STRATEGIES TARGETING THE HIV SANC
    Bradley Anderson; Fiscal Year: 2003
    ..Secondly, we wish to conduct in vivo studies aimed at improving therapy using existing drug combinations through enhanced CNS delivery...